Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States

By Ronald C. Kessler, M. Petukhova, N. Sampson, Alan M. Zaslavsky, Hans-Ulrich Wittchen. International Journal of Methods in Psychiatric Research, 2012

2,703 citations recorded by the source corpus.

Estimates of 12‐month and lifetime prevalence and of lifetime morbid risk (LMR) of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM‐IV‐TR) anxiety and mood disorders are presented based on US epidemiological surveys among people aged 13+. The presentation is designed for use in the upcoming DSM‐5 manual to provide more coherent estimates than would otherwise be available. Prevalence estimates are presented for the age groups proposed by DSM‐5 workgroups as the most useful to consider for policy planning purposes. The LMR/12‐month prevalence estimates ranked by frequency are as follows: major depressive episode: 29.9%/8.6%; specific phobia: 18.4/12.1%; social phobia: 13.0/7.4%; post‐traumatic stress disorder: 10.1/3.7%; generalized anxiety disorder: 9.0/2.0%; separation anxiety disorder: 8.7/1.2%; panic disorder: 6.8%/2.4%; bipolar disorder: 4.1/1.8%; agoraphobia: 3.7/1.7%; obsessive‐compulsive disorder: 2.7/1.2. Four broad patterns of results are most noteworthy: first, that the most common (lifetime prevalence/morbid risk) lifetime anxiety‐mood disorders in the United States are major depression (16.6/29.9%), specific phobia (15.6/18.4%), and social phobia (10.7/13.0%) and the least common are agoraphobia (2.5/3.7%) and obsessive‐compulsive disorder (2.3/2.7%); second, that the anxiety‐mood disorders with the earlier median ages‐of‐onset are phobias and separation anxiety disorder (ages 15–17) and those with the latest are panic disorder, major depression, and generalized anxiety disorder (ages 23–30); third, that LMR is considerably higher than lifetime prevalence for most anxiety‐mood disorders, although the magnitude of this difference is much higher for disorders with later than earlier ages‐of‐onset; and fourth, that the ratio of 12‐month to lifetime prevalence, roughly characterizing persistence, varies meaningfully in ways consistent with independent evidence about differential persistence of these disorders. Copyright © 2012 John Wiley & Sons, Ltd.

Subfields: Clinical Psychology, Experimental and Cognitive Psychology

View Paper: https://www.semanticscholar.org/paper/14194218dd4982a976d783cac55c57bb81b90cd2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Clinical Psychology

In Experimental and Cognitive Psychology

Citations in the corpus

Mental Health Smartphone Apps: Review and Evidence-Based Recommendations for Future Developments (2016, neutral): “7% suffering from an anxiety disorder at some point throughout their lives [75].”
The Yale–Brown Obsessive Compulsive Scale (2015, result): “Lifetime prevalence rates for OCD also vary, with figures of 1% and 1.6% for men and women in the Somers et al. (2006) study, and of 1.6% and 3%, respectively, in the Kessler et al. (2012) study.”
The role of oxytocin in social bonding, stress regulation and mental health: an update on the moderating effects of context and interindividual differences. (2013, background): “The presence of different effects of oxytocin treatment in males and females is of particular interest since females have an increased risk of developing anxiety disorders compared to males (Kessler et al., 2012).”
COGNITIVE DEFICITS AND FUNCTIONAL OUTCOMES IN MAJOR DEPRESSIVE DISORDER: DETERMINANTS, SUBSTRATES, AND TREATMENT INTERVENTIONS (2013, background): “INTRODUCTION Major depressive disorder (MDD) is a multidimensional mental disorder affecting approximately one in seven individuals at some time in their life.[1] MDD is associated with a high rate of nonrecovery and recurrence, with chronicity rates estimated at approximately 20%.”
Large-scale network dysfunction in Major Depressive Disorder: Meta-analysis of resting-state functional connectivity (2015, positive): “Exclusion criteria were: (1) no HC group or no current MDD group; (2) nonseed-based method; (3) whole-brain results could not be retrieved or did not survive correction (meta-analyses of fMRI data test for consistency in the spatial location of significant effects across studies;22 thus, only studie”